What happened at the USPTO PTAB Life Sciences Listening Session?

Panelists clashed over patent thickets and PTAB practices; pharma defended strong IP, generics praised IPRs for access.

What are patent thickets in pharma?

Clusters of 10+ patents around one drug, accused of blocking generics — but critics say data's dodgy and innovation needs 'em.

When are the next USPTO PTAB listening sessions?

High Tech on April 20, 3-5 p.m. ET; Administration and Reform on May 18, same time.

©️ IP & Copyright

Fireworks at USPTO's PTAB Life Sciences Clash: Patents, Thickets, and the Fight for Pharma's Future

Picture this: A USPTO room crackling with tension as patent warriors duke it out over 'thickets' choking drug innovation. Peter-Anthony Pappas drops a truth bomb — changes must chase facts, not fables.

theAIcatchup Apr 08, 2026 4 min read

Panel debate at USPTO PTAB Life Sciences Listening Session with speakers at podium

⚡ Key Takeaways

Pharma leaders like Pappas and Hadad urge PTAB reforms to protect innovation from serial challenges. 𝕏
Generics rep Cerwinski hails IPRs as a public win, but faces pushback on 'patent thicket' claims. 𝕏
Strong U.S. patents fuel AI-biotech future; reforms critical to maintain global lead. 𝕏

Published by

theAIcatchup

Where law meets technology.

#PTAB reforms #USPTO PTAB #life sciences patents #patent thickets #pharma IP #pharma IP reform

Worth sharing?

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog

⚡ Key Takeaways

The 60-Second TL;DR

theAIcatchup

Share this article

Worth sharing?

Related Stories

Inventors Are Starving in Big Tech's Shadow — AI Could Shatter the Status Quo

Federal Circuit Drops the Hammer: Patents Die Without All Inventors Post-AIA

Why Washington’s Chasing a Pharma Patent Ghost

Disney's 'This Is the Way' Blueprint for AI Copyright Survival

Stay in the loop